References

  1. WHO. World Malaria Report. 2015. Accessed on June 14, 2016.

  2. Noor AM, Kinyoki DK, Mundia CW et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. Lancet. 2014 May 17;383(9930):1739-47. PubMed | Google Scholar

  3. Bhatt S, Weiss DJ, Cameron E et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015 Oct 8;526(7572):207-11. PubMed | Google Scholar

  4. Pluess B, Tanser FC, Lengeler C, Sharp BL. Indoor residual spraying for preventing malaria. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006657. PubMed | Google Scholar

  5. Protopopoff N, Matowo J, Malima R et al. High level of resistance in the mosquito Anopheles gambiae to pyrethroid insecticides and reduced susceptibility to bendiocarb in north-western Tanzania. Malar J. 2013 May 2;12:149. PubMed | Google Scholar

  6. European Medicine Agencies, CHMP. Assessment report Mosquirix, 2015. Accessed on April 7, 2016.

  7. WHO. Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec. 2016 Jan 4;91(4):33-51. PubMed | Google Scholar

  8. Cohen J, Nussenzweig V, Nussenzweig R et al. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin. 2010 Jan;6(1):90-6. PubMed | Google Scholar

  9. Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines. 2011 May;10(5):589-99. PubMed | Google Scholar

  10. Mosquirix Product Information, 2015. Accessed on April 7, 2016.

  11. Birkett AJ. Status of vaccine research and development of vaccines for malaria. Vaccine. 2016 Jun 3;34(26):2915-20. PubMed | Google Scholar

  12. WHO. WHO Expert Committee on Biological Standardization 63rd report, Annex 3: Guidelines on the quality, safety and efficacy of recombinant malaria vaccines targeting the pre-erythrocytic and blood stages of Plasmodium falciparum, 2014. Accessed on 27 April 2016.

  13. Agnandji ST, Fernandes JF, Bache EB, Ramharter M. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. Future Microbiol. 2015;10(10):1553-78.| Google Scholar

  14. Ansong D, Asante KP, Vekemans J et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One. 2011; 6(4): e18891. Google Scholar

  15. Owusu-Agyei S, Ansong D, Asante K et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One. 2009 Oct 2;4(10):e7302. Google Scholar

  16. Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011 Feb;11(2):102-9. Google Scholar

  17. Agnandji ST, Asante KP, Lyimo J et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis. 2010 Oct 1;202(7):1076-87. Google Scholar

  18. Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008 Dec 11;359(24):2521-32. PubMed | Google Scholar

  19. Ndungu FM, Mwacharo J, Kimani D et al. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PLoS One. 2012;7(12):e52870. Google Scholar

  20. Bejon P, Cook J, Bergmann-Leitner E et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis. 2011 Jul 1;204(1):9-18. PubMed | Google Scholar

  21. Olotu A, Moris P, Mwacharo J et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS One. 2011;6(10):e25786. Google Scholar

  22. Lusingu J, Olotu A, Leach A et al. Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children. PLoS One. 2010 Nov 29;5(11):e14090. PubMed | Google Scholar

  23. Asante KP, Abdulla S, Agnandji S et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011 Oct;11(10):741-9. Google Scholar

  24. Leach A, Vekemans J, Lievens M et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J. 2011 Aug 4;10:224. Google Scholar

  25. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015 Jul 4;386(9988):31-45. PubMed | Google Scholar

  26. Lievens M, Aponte JJ, Williamson J et al. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children. Malar J. 2011 Aug 4;10:222. PubMed | Google Scholar

  27. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014 Jul 29;11(7):e1001685. Google Scholar

  28. Neafsey DE, Juraska M, Bedford T et al. Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine. N Engl J Med. 2015 Nov 19;373(21):2025-37. PubMed | Google Scholar

  29. RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011 Nov 17;365(20):1863-75. PubMed | Google Scholar

  30. Swysen C, Vekemans J, Bruls M et al. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J. 2011 Aug 4;10:223. PubMed | Google Scholar

  31. Vekemans J, Marsh K, Greenwood B et al. Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. Malar J. 2011 Aug 4;10:221. PubMed | Google Scholar

  32. RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012 Dec 13;367(24):2284-95. PubMed | Google Scholar

  33. Otieno L, Oneko M, Otieno W et al. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2016 Oct;16(10):1134-1144. PubMed | Google Scholar

  34. Umeh R, Oguche S, Oguonu T et al. Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial. Vaccine. 2014 Nov 12;32(48):6556-62. PubMed | Google Scholar

  35. Vandoolaeghe P, Schuerman L. The RTS, S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination. Expert Rev Vaccines. 2016 Dec;15(12):1481-93. PubMed | Google Scholar

  36. Joint Technical Expert Group & World Health Organization. Background paper on the RTS,S/AS01 malaria vaccine, 2015. Accessed on April 7, 2016.

  37. Olotu A, Fegan G, Wambua J et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013 Mar 21;368(12):1111-20. PubMed | Google Scholar

  38. Olotu A, Fegan G, Wambua J et al. Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children. N Engl J Med. 2016 Jun 30;374(26):2519-29. PubMed | Google Scholar

  39. Bejon P, White MT, Olotu A et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis. 2013 Apr;13(4):319-27. PubMed | Google Scholar

  40. Reyburn H, Mbatia R, Drakeley C et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA. 2005 Mar 23;293(12):1461-70. PubMed | Google Scholar

  41. Taylor T, Olola C, Valim C et al. Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg. 2006 Jul;100(7):615-22. PubMed | Google Scholar

  42. Jallow M, Casals-Pascual C, Ackerman H et al. Clinical features of severe malaria associated with death: a 13-year observational study in the Gambia. PLoS One. 2012;7(9):e45645. PubMed | Google Scholar

  43. Dondorp AM, Fanello CI, Hendriksen IC et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010 Nov 13;376(9753):1647-57. PubMed | Google Scholar

  44. Hamel MJ, Oneko M, Williamson J et al. A marked reduction in mortality among participants in a clinical trial that removed barriers to care and implemented national case management guidelines. 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene; New Orleans, USA; Nov 2–6, 2014. 631 (abstr). Google Scholar

  45. Alloueche A, Milligan P, Conway DJ et al. Protective efficacy of the RTS, S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. The American journal of tropical medicine and hygiene. 2003;68(1):97-101. Google Scholar

  46. Enosse S, Dobaño C, Quelhas D et al. RTS, S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLOS Clin Trial. 2006;1(1):e5. Google Scholar

  47. Waitumbi JN, Anyona SB, Hunja CW et al. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P falciparum in adults participating in a malaria vaccine clinical trial. PLoS One. 2009 Nov 17;4(11):e7849. Google Scholar

  48. Penny MA, Verity R, Bever CA et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016 Jan 23;387(10016):367-75. Google Scholar

  49. Penny MA, Pemberton-Ross P, Smith TA. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease. Malar J. 2015 Nov 4;14:437. Google Scholar

  50. Agnandji ST, Fendel R, Mestre M et al. Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D). PLoS One. 2011 Apr 11;6(4):e18559. PubMed | Google Scholar

  51. Ajua A, Lell B, Agnandji ST et al. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants. Malar J. 2015 Feb 13;14:72. Google Scholar

  52. Horowitz A, Hafalla JC, King E et al. Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. J Immunol. 2012 May 15;188(10):5054-62. Google Scholar

  53. Kester KE, Cummings JF, Ofori-Anyinam O et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009 Aug 1;200(3):337-46. Google Scholar

  54. White MT, Verity R, Griffin JT et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015 Dec;15(12):1450-8. Google Scholar

  55. Vekemans J, Guerra Y, Lievens M et al. Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials. Hum Vaccin. 2011 Dec;7(12):1309-16. Google Scholar

  56. Guerra Mendoza Y, Garric E, Schuerman L et al. Discussion of meningitis, cerebral malaria and all-cause mortality followind immunization of children with the RTS,S/AS01 malaria vaccine in the phase III efficacy trial. MVW, Leiden, Netherlands. 2-5 May 2016.

  57. Klein SL, Shann F, Moss WJ et al. RTS,S Malaria Vaccine and Increased Mortality in Girls. MBio. 2016 Apr 26;7(2):e00514-16. Google Scholar